Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Other Accumulated Expenses (2016 - 2017)

Dare Bioscience's Other Accumulated Expenses history spans 5 years, with the latest figure at $120000.0 for Q2 2017.

  • For Q2 2017, Other Accumulated Expenses fell 83.07% year-over-year to $120000.0; the TTM value through Jun 2017 reached $120000.0, down 83.07%, while the annual FY2016 figure was $575000.0, 34.88% down from the prior year.
  • Other Accumulated Expenses reached $120000.0 in Q2 2017 per DARE's latest filing, down from $300000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $883000.0 in Q4 2015 to a low of $27000.0 in Q2 2015.
  • Average Other Accumulated Expenses over 5 years is $387333.3, with a median of $339000.0 recorded in 2014.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 91.87% in 2015, then surged 2525.93% in 2016.
  • A 5-year view of Other Accumulated Expenses shows it stood at $379000.0 in 2013, then crashed by 91.03% to $34000.0 in 2014, then soared by 2497.06% to $883000.0 in 2015, then plummeted by 34.88% to $575000.0 in 2016, then tumbled by 79.13% to $120000.0 in 2017.
  • Per Business Quant, the three most recent readings for DARE's Other Accumulated Expenses are $120000.0 (Q2 2017), $300000.0 (Q1 2017), and $575000.0 (Q4 2016).